Figure 1.

Time to second primary tumor according to the treatment given for the first primary tumor.

(A) Time to second primary tumor in patients treated with immunotherapy and/or cytotoxic chemotherapy or none for the first primary cancer (all patients). (B) Time to second primary tumor in patients treated with immunotherapy and/or cytotoxic chemotherapy or none for the first primary cancer in patients without documented metastasis. Survival analysis was carried out using competing risk analysis to estimate the risk of being alive without second primary cancer (SPC) and 6-months landmark analysis to limit analysis to subjects who have survived long enough for treatment to be initiated. Due to this last constraint, 12 432 patients (26.5%) with SPC or death before 6 months were excluded from the survival analysis. Thus, the population in this analysis consists of 34 397 patients. CI, confidence interval; CIF est., cumulative incidence function with competing risks data; FPC, first primary cancer; HR, hazard ratio; NE, not evaluable.